Department of Urology, Shiga University of Medical Science, Shiga, Japan.
Central Research Laboratory, Shiga University of Medical Science, Shiga, Japan.
Cancer Biomark. 2018;22(4):755-761. doi: 10.3233/CBM-181308.
Renal cell carcinoma (RCC) is the urological malignancy with the highest mortality rate and is increasing in incidence. The prognostic and predictive biomarkers are highly desired. This study aims to investigate the significance of superoxide dismutase 2 (SOD2) as a clinical biomarker in patients with renal cell carcinomas.
A cohort of 97 patients with RCC was analyzed retrospectively using various clinical parameters and SOD2 expression by immunohistochemistry.
Cases with stronger SOD2 positivity of the tumor in comparison to the adjacent normal renal tubule by immunohistochemistry were categorized as high SOD2 and were associated with worse overall survivals (p= 0.005). In particular, in cases with metastatic RCC, high SOD2 expression in the tumors was significantly associated with a worse overall survival (p= 0.001), and the maximum critical risk. Treatment with current molecular targeting therapies did not improve the prognoses of cases with metastatic or recurrent RCC.
High SOD2 expression can be predictive of a poor clinical outcome and be clinically useful in the follow-up of metastatic RCC. Therapeutics for metastatic RCCs require further improvement, such as supplementary administration of agents targeting mitochondrial SOD2.
肾细胞癌（RCC）是泌尿生殖系统恶性肿瘤中死亡率最高的肿瘤，且发病率呈上升趋势。人们迫切需要寻找预测预后的生物标志物。本研究旨在探讨超氧化物歧化酶 2（SOD2）作为肾细胞癌患者临床生物标志物的意义。
回顾性分析了 97 例 RCC 患者的各种临床参数和免疫组织化学检测的 SOD2 表达情况。
与相邻正常肾小管相比，肿瘤中 SOD2 免疫组织化学染色阳性强度更高的病例被归类为高 SOD2，并与更差的总生存率相关（p=0.005）。特别是在转移性 RCC 病例中，肿瘤中高 SOD2 表达与更差的总生存率显著相关（p=0.001），为最大临界风险。目前的分子靶向治疗并不能改善转移性或复发性 RCC 病例的预后。
高 SOD2 表达可预测不良临床结局，对转移性 RCC 的随访具有临床意义。转移性 RCC 的治疗需要进一步改善，例如补充针对线粒体 SOD2 的靶向治疗药物。
